Philip M. Zakas

Philip M. Zakas

Auto-generated profile, based on publicly available information

Philip M. Zakas

Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2016 in Nature Communications
Verified
Journal Article
Open access
WDWei Deng
Wei Deng
YXYan Xu
Yan Xu
WCWenchun Chen
Wenchun Chen
DPDavid S. Paul
David S. Paul
AKAnum Kazerouni
Anum Kazerouni
RLRenhao Li
Renhao Li
Mechanisms by which blood cells sense shear stress are poorly characterized. In platelets, glycoprotein (GP)Ib–IX receptor complex has been long suggested to be a shear sensor and receptor. Recently, a relatively unstable and mechanosensitive domain in the GPIbα subunit of GPIb–IX was identified. Here we show that binding of its ligand, von Willebrand factor, under physiological shear stress induces unfolding of this mechanosensory domain (MSD) on the platelet surface. The unfolded MSD, particularly the juxtamembrane ‘Trigger’ sequence therein, leads to intracellular signalling and rapid platelet clearance. These results illustrate the initial molecular event underlying platelet shear sensing and provide a mechanism linking GPIb–IX to platelet clearance. Our results have implications on the mechanism of platelet activation, and on the pathophysiology of von Willebrand disease and related thrombocytopenic disorders. The mechanosensation via receptor unfolding may be applicable for many other cell adhesion receptors.

26 September 2016 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
PZPhilip M Zakas
Philip M Zakas
HBHarrison C Brown
Harrison C Brown
KKKristopher Knight
Kristopher Knight
SMShannon Meeks
Shannon Meeks
HSH Trent Spencer
H Trent Spencer
CDChristopher B Doering
Christopher B Doering
The pharmaceutical properties of coagulation factor VIII are improved by reconstructing the protein's ancestral sequence. Optimization of a protein's pharmaceutical properties is usually carried out by rational design and/or directed evolution. Here we test an alternative approach based on ancestral sequence reconstruction. Using available genomic sequence data on coagulation factor VIII and predictive models of molecular evolution, we engineer protein variants with improved activity, stability, and biosynthesis potential and reduced inhibition by anti-drug antibodies. In principle, this approach can be applied to any protein drug based on a conserved gene sequence.

5 February 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
PZPhilip M. Zakas
Philip M. Zakas
CCChristopher W. Coyle
Christopher W. Coyle
ABAnja Brehm
Anja Brehm
MBMarion Bayer
Marion Bayer
BSBarbara Solecka-Witulska
Barbara Solecka-Witulska
DLDavid Lillicrap
David Lillicrap
Ancestral sequence reconstruction provides a unique platform for investigating the molecular evolution of single gene products and recently has shown success in engineering advanced biological therapeutics. To date, the coevolution of proteins within complexes and protein–protein interactions is mostly investigated in silico via proteomics and/or within single-celled systems. Herein, ancestral sequence reconstruction is used to investigate the molecular evolution of 2 proteins linked not only by stabilizing association in circulation but also by their independent roles within the primary and secondary hemostatic systems of mammals. Using sequence analysis and biochemical characterization of recombinant ancestral von Willebrand factor (VWF) and coagulation factor VIII (FVIII), we investigated the evolution of the essential macromolecular FVIII/VWF complex. Our data support the hypothesis that these coagulation proteins coevolved throughout mammalian diversification, maintaining strong binding affinities while modulating independent and distinct hemostatic activities in diverse lineages.